Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater.
John P. Neoptolemos(University of Liverpool), Malcolm J. Moore(University Health Network), M. W. Büchler(Cancer Research UK), Charlotte Rawcliffe(University of Liverpool), Paula Ghaneh(University of Liverpool), F Lacaine(Sorbonne Université), Daniel H. Palmer(Cancer Research UK Clinical Trials Unit), Attila Oláh(Semmelweis University), Mark R. Middleton(University of Oxford), Bengt Glimelius(Uppsala University), Claudio Bassi(University of Verona), Juan W. Valle(The Christie NHS Foundation Trust), Niall C. Tebbutt(Peter MacCallum Cancer Centre), Christopher Halloran(University of Liverpool), Trevor F. Cox(University of Liverpool), David B. Smith(Wirral University Teaching Hospital NHS Foundation Trust), C. Dervenis(Cancer Research UK), A. McDonald(Cancer Research UK), Fareeda Y. Coxon(Newcastle upon Tyne Hospitals NHS Foundation Trust), R. Carter(Cancer Research UK)
Cited by 24
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k